TIFACT Study - Tissue Factor Expression by Adipose Tissue in Extremely Obese Subjects.
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Tissue factor is the main activator of coagulation cascades. Excessive tissue factor expression is made responsible of thrombosis in a number of clinical situations including thrombosis in contact with atherosclerotic plaques. Recent work showed that tissue factor gene expression in adipose tissue was significantly increased in obese versus lean mice.
The main objective of this study is to show that tissue factor expression is increased in human adipose tissue obtained from obese subjects and to identify its main tissular origin by comparing abdominal and subcutaneous adipose tissue.
The secondary objectives are to identify the cell origin of tissue factor (adipocytes versus stromal cells) and to analyze the relation ship between blood tissue factor and (i) tissue factor expressed by adipose tissue, (ii) the amount of subcutaneous and profound adipose tissue, and (iii) coagulation activation markers.
| Condition |
|---|
|
Obesity |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | TIFACT Study - Tissue Factor Expression by Adipose Tissue in Extremely Obese Subjects. Relationship With Circulating Tissue Factor and Coagulation Activation Markers |
samples of plasma and serum and greasy fragments
| Enrollment: | 85 |
| Study Start Date: | October 2006 |
| Study Completion Date: | October 2010 |
| Primary Completion Date: | October 2010 (Final data collection date for primary outcome measure) |
Tissue factor is the main activator of coagulation cascades. Excessive tissue factor expression is made responsible of thrombosis in a number of clinical situations including thrombosis in contact with atherosclerotic plaques. Recent work showed that tissue factor gene expression in adipose tissue was significantly increased in obese versus lean mice.
The main objective of this study is to show that tissue factor expression is increased in human adipose tissue obtained from obese subjects and to identify its main tissular origin by comparing abdominal and subcutaneous adipose tissue.
The secondary objectives are to identify the cell origin of tissue factor (adipocytes versus stromal cells) and to analyze the relation ship between blood tissue factor and (i) tissue factor expressed by adipose tissue,
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Inclusion Criteria:
- BMI > 35
- Stable obesity
- Abdominal or pelvic surgery
- Agree to participate to the study
Exclusion Criteria:
- malignancy,
- infectious or inflammatory disease, notably HIV infection
- pregnancy
- history of ischemic cardio or neurovascular event, lower limb arteritis
Inclusion Criteria:
- BMI > 35
- Stable obesity
- Abdominal or pelvic surgery
- Agree to participate to the study
Exclusion Criteria:
- malignancy,
- infectious or inflammatory disease, notably HIV infection
- pregnancy
- history of ischemic cardio or neurovascular event, lower limb arteritis
Contacts and Locations| France | |
| CHU Louis Mourier | |
| Colombes, France, 92701 | |
| Principal Investigator: | Alain STEPANIAN, MD PH | Assistance Publique - Hôpitaux de Paris |
More Information
Publications:
| Responsible Party: | Assistance Publique - Hôpitaux de Paris |
| ClinicalTrials.gov Identifier: | NCT00379704 History of Changes |
| Other Study ID Numbers: | P060307 |
| Study First Received: | September 21, 2006 |
| Last Updated: | December 7, 2011 |
| Health Authority: | France: Ministry of Health |
Keywords provided by Assistance Publique - Hôpitaux de Paris:
|
Tissue factor Obesity Adipose tissue Microparticles |
Additional relevant MeSH terms:
|
Obesity Overnutrition Nutrition Disorders Overweight Body Weight Signs and Symptoms |
Thromboplastin Hemostatics Coagulants Hematologic Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 21, 2013